Caffeine, coffee and the heart: AHA 2026 statement
What can a manufacturer say on an EU label?

On 20 July 2026, Circulation published the American Heart Association scientific statement “Caffeine and Cardiovascular Disease” (doi: 10.1161/CIR.0000000000001454). The writing group was chaired by Prof. Gregory M. Marcus of UCSF. The document summarises the current state of knowledge on the effects of caffeine and coffee on the cardiovascular system. From the perspective of a food manufacturer operating in the EU, however, what matters most is not what science says — but what the law permits on the label.

What the AHA statement says: key findings

The statement is based on a review of dozens of epidemiological studies, several randomised clinical trials and mechanistic data. Main conclusions:

• Up to 400 mg of caffeine per day is the toxicological safety limit for most healthy adults, not a universal recommendation for a number of cups; caffeine content per cup varies considerably.
• Moderate coffee consumption in observational studies is associated with lower risk of coronary heart disease, stroke, heart failure and type 2 diabetes.
• The DECAF trial is one of the intervention studies discussed in relation to atrial fibrillation; its results should not be presented as general evidence that coffee prevents disease recurrence.
• Findings on coffee quantity and heart failure do not define a universal threshold; the precise risk depends on the population, preparation method and individual response.
• Energy drinks and caffeine shots should not be treated like coffee — clinical case reports indicate a risk of arrhythmia and hypertension.
• Most data are observational in nature — they do not prove a cause-and-effect relationship.
• Benefits may stem not from caffeine itself but from other compounds in coffee (antioxidants, polyphenols, anti-inflammatory substances).
• Individual response varies — depending on genetics (CYP1A2 metabolism), habits, age and comorbidities.

The EFSA opinion on caffeine safety — what it says and what it does not

In 2015, the EFSA NDA Panel issued a scientific opinion “Scientific Opinion on the safety of caffeine” (EFSA Journal 2015;13(5):4102). Its scope is strictly limited to toxicological safety:

• Up to 400 mg/day — safe for non-pregnant adults
• Up to 200 mg/day — safe for pregnant women
• Single doses up to 200 mg — do not raise safety concerns

Key caveat: the EFSA opinion assesses safety only. It does not assess the health benefits of caffeine. It does not provide a basis for any health claims. It says nothing about heart protection, reduced diabetes risk or improved vascular health. It is a toxicological opinion, not a health recommendation.

Status of health claims for caffeine in the EU

An important clarification: there is currently no authorised health claim for caffeine. Four applications relating to increased alertness, attention and endurance received positive EFSA opinions but were never authorised or entered into the binding EU list. They may therefore not be presented as claims permitted under Regulation 432/2012.

The values of 75 mg per serving and 3 mg/kg body weight one hour before exercise were conditions of use contained in a rejected, non-binding proposal. They are not currently conditions of any lawful health claim for caffeine.

There are no authorised claims relating to: heart protection, reduced stroke risk, reduced diabetes risk, improved vascular health, reduced heart failure risk, or increased alertness, attention or endurance.

Why a manufacturer cannot use the AHA statement on the European market

The EU legal framework rests on two pillars that together create an insurmountable barrier:

• Article 10(1) of Regulation 1924/2006: only health claims that are authorised and entered in the EU register may be used.
• Article 7(3) of Regulation 1169/2011: food information must not attribute to a food the property of preventing, treating or curing a human disease.

In practice this means:

• The text “coffee protects the heart” on packaging = an unlawful health claim
• The claim “reduces the risk of diabetes” in marketing materials = a breach of law
• Referencing the AHA statement as justification for a health claim = insufficient; a scientific publication alone does not replace authorisation and entry in the EU register
• General, factual information about a scientific publication requires separate assessment of context; it must not suggest that caffeine or coffee confers a specific health benefit on the consumer.

CJEU judgment in Case C-363/19 — an important clarification

In Case C-363/19, the Court of Justice clarified that general, non-specific references to health or well-being in commercial communications must be linked to a specific authorised health claim from the EU lists. The judgment did not authorise any claim for caffeine and cannot transform a positive EFSA opinion or the AHA statement into an authorised claim. Since there is currently no authorised health claim for caffeine, adding a general slogan such as “good for the heart” does not remedy the legal problem.

flowchart TD
    A[Producent chce wykorzystac\nwyniki stanowiska AHA\nna etykiecie w UE] --> B{Jaki typ\nkomunikatu?}
    B -->|Rzetelna informacja ogolna\nbez sugestii zdrowotnej| D[Dopuszczalne po ocenie\nkontekstu; bez obietnicy\nkorzysci zdrowotnej]
    B -->|Oswiadczenie zdrowotne\nart. 13 lub art. 14| C{Czy kofeina ma\nautoryzowane oswiadczenie\nw unijnym rejestrze?}
    C -->|Nie - obecnie brak| F[NIELEGALNE\nart. 10 rozp. 1924/2006]
    C -->|Tak - sprawdz aktualny wpis| G[Uzyj tylko dokladnego\nbrzmienia i warunkow\nz wpisu]
    D --> H{Czy komunikat sugeruje\nkonkretna korzysc zdrowotna?}
    H -->|Tak| F
    H -->|Nie| I[Informacja ogolna\nbez oswiadczenia zdrowotnego]
    style F fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style G fill:#064e3b,stroke:#10b981,color:#d1fae5
    style D fill:#1e3a8a,stroke:#38bdf8,color:#dbeafe
    style I fill:#064e3b,stroke:#10b981,color:#d1fae5

EFSA opinion vs. AHA statement — comparing their scope

These two documents are frequently confused or treated interchangeably. They differ fundamentally in scope, purpose and legal consequences:

flowchart LR
    subgraph EFSA["OPINIA EFSA 2015 (4102)"]
        direction TB
        E1[Zakres: bezpieczenstwo\ntoksykologiczne kofeiny]
        E2[Mowi: bezpieczne limity\nspożycia 400 mg/dzien]
        E3[NIE mowi: nic o\nkorzysciach zdrowotnych]
        E4[Skutek prawny: brak\npodstawy do oswiadczen\nzdrowotnych]
        E5[Cztery pozytywne opinie\nEFSA nie zostaly\nautoryzowane]
    end
    subgraph AHA["STANOWISKO AHA 2026"]
        direction TB
        A1[Zakres: przeglad asocjacji\nkawa/kofeina a CVD]
        A2[Mowi: korelacja z nizszym\nryzykiem choroby wiencowej\nudaru niewydolnosci serca]
        A3[NIE mowi: nie dowodzi\nprzyczynowosci]
        A4[Skutek prawny: brak\njakiegokolwiek skutku\nw prawie UE]
    end
    EFSA -.->|Zaden dokument nie\nautoryzuje oswiadczen\no kofeinie lub sercu w UE| AHA
    style E4 fill:#1e293b,stroke:#f59e0b,color:#fbbf24
    style A4 fill:#1e293b,stroke:#f59e0b,color:#fbbf24

Practical implications for manufacturers and importers

The AHA statement changes the scientific picture, but it does not change the law. Practical implications:

• Manufacturers of caffeine food supplements — may not present the AHA findings as health claims in consumer communications in the EU. General factual information requires assessment of context and must not suggest an unauthorised health benefit.
• Coffee manufacturers — may not currently use any authorised health claim for caffeine. The values of 75 mg and 3 mg/kg from the former proposal are not conditions of any lawful health claim.
• Importing products from the US bearing cardioprotective claims — placing on the EU market a product whose label suggests heart protection constitutes a breach of food labelling law.
• Energy drinks — a separate risk category. The EU already requires the warning “High caffeine content”; the AHA statement further underlines the risk of arrhythmia at high doses.

Energy drinks — a separate risk

The AHA statement clearly distinguishes coffee from energy drinks and caffeine shots. Key warnings:

• Case reports of cardiac arrhythmias following energy drink consumption
• High caffeine concentrations combined with other stimulants may produce a synergistic effect
• Absence of long-term safety data for this product category

In the EU, energy drinks are subject to labelling requirements under Regulation 1169/2011 (mandatory warning: “High caffeine content. Not recommended for children, pregnant women or breastfeeding women”), while further sales restrictions remain within the competence of individual Member States.

Conclusions

The AHA statement of July 2026 is a sound summary of the current state of science — and for an individual it may well be a reason to continue drinking coffee without concern. For a food or food supplement manufacturer operating in the EU, however, the document changes nothing in the legal sphere. The gap between scientific observation and regulatory authorisation is intentional: it protects consumers from the conversion of statistical correlations into marketing promises.

A manufacturer wishing to lawfully communicate the health properties of caffeine in the EU cannot rely on a positive EFSA opinion or the AHA statement. What would be required is authorisation of an appropriate claim by the European Commission following an EFSA assessment; as of today, no such claim exists for caffeine. The values of 75 mg and 3 mg/kg should be treated solely as elements of a rejected, non-binding proposal, and not as a basis for marketing communications.

Disclaimer: Tomasz Krawczyk — author of content on EU and Polish food law and food supplements. supplemental.pl · foodlaw.ai. This material is for general information purposes only and reflects the legal position as of July 2026; it does not constitute legal advice in any individual matter.